X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs CIPLA - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. CIPLA WOCKHARDT LTD./
CIPLA
 
P/E (TTM) x -15.8 44.6 - View Chart
P/BV x 2.6 3.8 67.7% View Chart
Dividend Yield % 1.3 0.3 379.1%  

Financials

 WOCKHARDT LTD.   CIPLA
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-17
CIPLA
Mar-17
WOCKHARDT LTD./
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,129622 181.5%   
Low Rs627458 136.8%   
Sales per share (Unadj.) Rs363.1181.9 199.7%  
Earnings per share (Unadj.) Rs-20.412.9 -158.9%  
Cash flow per share (Unadj.) Rs-7.029.3 -23.8%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %1.10.4 307.6%  
Book value per share (Unadj.) Rs301.8155.7 193.9%  
Shares outstanding (eoy) m110.55804.51 13.7%   
Bonus/Rights/Conversions ISESOP-  
Price / Sales ratio x2.43.0 81.4%   
Avg P/E ratio x-42.942.0 -102.3%  
P/CF ratio (eoy) x-125.918.4 -683.2%  
Price / Book Value ratio x2.93.5 83.9%  
Dividend payout %-48.915.5 -314.7%   
Avg Mkt Cap Rs m97,063434,516 22.3%   
No. of employees `0006.823.0 29.4%   
Total wages/salary Rs m9,66526,338 36.7%   
Avg. sales/employee Rs Th5,931.86,349.1 93.4%   
Avg. wages/employee Rs Th1,428.11,143.0 124.9%   
Avg. net profit/employee Rs Th-334.0449.3 -74.3%   
INCOME DATA
Net Sales Rs m40,146146,302 27.4%  
Other income Rs m1,1432,287 50.0%   
Total revenues Rs m41,289148,589 27.8%   
Gross profit Rs m12824,758 0.5%  
Depreciation Rs m1,48913,229 11.3%   
Interest Rs m2,2531,594 141.3%   
Profit before tax Rs m-2,47212,222 -20.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-2111,798 -11.7%   
Profit after tax Rs m-2,26010,354 -21.8%  
Gross profit margin %0.316.9 1.9%  
Effective tax rate %8.514.7 58.1%   
Net profit margin %-5.67.1 -79.6%  
BALANCE SHEET DATA
Current assets Rs m46,16087,370 52.8%   
Current liabilities Rs m19,25833,081 58.2%   
Net working cap to sales %67.037.1 180.6%  
Current ratio x2.42.6 90.8%  
Inventory Days Days10187 115.8%  
Debtors Days Days9462 150.9%  
Net fixed assets Rs m40,165111,567 36.0%   
Share capital Rs m5531,609 34.4%   
"Free" reserves Rs m32,814123,645 26.5%   
Net worth Rs m33,367125,254 26.6%   
Long term debt Rs m31,90336,454 87.5%   
Total assets Rs m89,687209,532 42.8%  
Interest coverage x-0.18.7 -1.1%   
Debt to equity ratio x1.00.3 328.5%  
Sales to assets ratio x0.40.7 64.1%   
Return on assets %05.7 -0.2%  
Return on equity %-6.88.3 -81.9%  
Return on capital %-0.38.5 -3.9%  
Exports to sales %034.2 0.0%   
Imports to sales %08.3 0.0%   
Exports (fob) Rs mNA50,050 0.0%   
Imports (cif) Rs mNA12,203 0.0%   
Fx inflow Rs m9,12151,066 17.9%   
Fx outflow Rs m2,13317,678 12.1%   
Net fx Rs m6,98833,388 20.9%   
CASH FLOW
From Operations Rs m-2,69523,824 -11.3%  
From Investments Rs m-6,863-13,127 52.3%  
From Financial Activity Rs m12,545-13,239 -94.8%  
Net Cashflow Rs m3,010-2,478 -121.5%  

Share Holding

Indian Promoters % 74.5 16.0 465.6%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 2.3 12.2 18.9%  
FIIs % 7.7 23.7 32.5%  
ADR/GDR % 0.1 1.1 9.1%  
Free float % 15.4 26.2 58.8%  
Shareholders   67,757 161,166 42.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   IPCA LABS  NOVARTIS  ALEMBIC PHARMA  ORCHID PHARMA LTD  SANOFI INDIA  

Compare WOCKHARDT LTD. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Feb 23, 2018 (Close)

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. 8-QTR ANALYSIS

COMPARE WOCKHARDT LTD. WITH

MARKET STATS